Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Esophagus to Small Intestine

    Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: A randomized trial

    Gastroenterology. 2023;164(1):61–71

    Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S

    Go to article

    Esophagus to Small Intestine

    Eosinophilic gastritis and enteritis are increased in families with eosinophilic esophagitis

    Am J Gastroenterol. 2023;118(2):263–8

    Allen-Brady K, Colletier KJ, Woller S, Eliason K, Uchida AM, Ro G, Newman M, Peterson KA

    Go to article

    Esophagus to Small Intestine

    Phase 2 trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis

    Gut. 2023;72(2):256–63

    Samadder NJ, Foster N, McMurray RP, Burke CA, Stoffel E, Kanth P, Das R, Cruz-Correa M, Vilar E, Mankaney G, Buttar N, Thirumurthi S, Turgeon DK, Sossenheimer M, Westover M, Richmond E, Umar A, Della’Zanna G, Rodriguez LM, Szabo E, Zahrieh D, Limburg PJ

    Go to article

    Esophagus to Small Intestine

    Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: A prospective 16-year longitudinal cohort study

    Lancet Oncol. 2023;24(1):107–16

    Lee CYC, Olivier A, Honing J, Lydon AM, Richardson S, O’Donovan M, Tischkowitz M, Fitzgerald RC, di Pietro M

    Go to article

    Esophagus to Small Intestine

    Prevalence and prognostic significance of vitamin C deficiency in patients with acute upper gastrointestinal bleeding: A prospective cohort study

    Aliment Pharmacol Ther. 2023;57(3):313–22

    Hui S, Lim A, Koh E, Abasszade J, Morgan A, Tan PY, Lemoh C, Robertson M

    Go to article

    Esophagus to Small Intestine

    Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): A multicenter, open-label, randomized controlled trial

    Lancet Gastroenterol Hepatol. 2023;8(3):215–27

    Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D’Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group

    Go to article

    Esophagus to Small Intestine

    Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: A GETAID multicenter cohort study

    Aliment Pharmacol Ther. 2023;57(4):426–34

    Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L

    Go to article

    Esophagus to Small Intestine

    Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn’s disease

    Clin Gastroenterol Hepatol. 2023;21(1):153–63.e12

    Kucharzik T, Wilkens R, D’Agostino MA, Maconi G, Le Bars M, Lahaye M, Bravatà I, Nazar M, Ni L, Ercole E, Allocca M, Machková N, de Voogd FAE, Palmela C, Vaughan R, Maaser C; STARDUST Intestinal Ultrasound study group

    Go to article

    Esophagus to Small Intestine

    Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: When the remission state hides different types of residual disease activity

    Gut. 2023;72(3):443–50

    Pierre N, Huynh-Thu VA, Marichal T, Allez M, Bouhnik Y, Laharie D, Bourreille A, Colombel JF, Meuwis MA, Louis E; GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif)

    Go to article